We examined the relationship between p53 expression and clinicopatholo
gic parameters in anal carcinoma. p53 immunoreactivity was detected in
14/18 (77.7%) tumors. Significant association was found between p53 e
xpression and depth of invasion. There was no significant association
between p53 expression and histologic type, lymph node metastasis, age
and prognosis. Possibly the genetic pathway to anal carcinoma involvi
ng p53 gene overexpression confer aggressive growth pattern, but it do
es not result in worse prognosis. The absence of correlation between p
53 overexpression and prognosis could be explained by tumors negative
for mutations having an excess of wild-type p53 protein.